Publication:
The effect of montelukast on early-life wheezing: a randomized, double-blinded placebo-controlled study

Placeholder

Departments

Organizational Unit

School / College / Institute

Organizational Unit
SCHOOL OF MEDICINE
Upper Org Unit

Program

KU Authors

Co-Authors

Keskin, Özlem
Yılmaz, Ebru Arık
Motzkus, Christine
Lilly, Craig M.
Kalaycı, Ömer

Publication Date

Language

Embargo Status

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Background: Cysteinyl-leukotrienes are increased in the airways of infants with virus-associated wheezing. We aimed to determine the effects of a cysteinyl-leukotriene-1 receptor antagonist on symptoms during an early-life wheezing illness and to investigate the factors that affect the response to this drug. Method: This placebo-controlled double-blinded randomized controlled trial recruited children aged 3-36 months with wheezing illness and randomized to active drug or placebo for 56 days. A symptom score diary (SSD) was kept by the children's caregivers. Results: One-hundred patients completed the study, and 62 (30 montelukast and 32 placebo) were analyzed. There were no significant differences in the percent of symptom-free days, symptom scores, and the need for rescue salbutamol between the two groups. However, the percent of symptom-free days within the first week was significantly higher for the montelukast than for the placebo group (13.8 +/- 4.1% vs. 5.4 +/- 3.4%; P = 0.028); wheezing score at 7th day was significantly lower for the montelukast than for the placebo group (0.5 +/- 0.1 vs. 1.4 +/- 0.2; P = 0.002). In addition, the number of inhaled ss 2-agonist rescue episodes per day during the first week was significantly lower for the montelukast compared with the placebo group (12.7 +/- 1.8 vs. 19.2 +/- 1.6; P = 0.013). Conclusions: Our results indicate that montelukast may be effective for reducing caregiver-observed wheezing and the need for salbutamol during the first week of treatment for early-life wheezing. The impact for caregivers and the optimal duration of treatment will need to be explored in studies of larger size.

Source

Publisher

Wiley

Subject

Allergy, Immunology, Pediatrics

Citation

Has Part

Source

Pediatric Allergy and Immunology

Book Series Title

Edition

DOI

10.1111/pai.12822

item.page.datauri

Link

Rights

Copyrights Note

Endorsement

Review

Supplemented By

Referenced By

0

Views

0

Downloads

View PlumX Details